**UNITEDSTATES**

**SECURITIESAND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

 

**FORM 10-Q/A**

**(Amendment No. 1)**

 

| **x**      | **Quarterly Report Under  Section 13 or 15(d) of the Securities Exchange Act of 1934****For the quarterly period ended March 31, 2008**                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| **o**      | **Transition Report pursuant to  Section 13 or 15(d) of the Securities Exchange Act of 1934****For the transition period from                                          to                                      .** |

 

**Commissionfile number 001-15070**

 

**REGENERXBIOPHARMACEUTICALS, INC.**

(Exact Name of Registrantas Specified in its Charter)

 

| **Delaware**              | ** ** | **52-1253406**              |
|---------------------------|------------|-----------------------------|
| (State of  Incorporation) |       | (IRS Employer I.D.  Number) |
|                      |       |                        |

**3 Bethesda Metro Center**

**Suite 630**

**Bethesda, Maryland 20814**

(Address of PrincipalExecutive Offices)

 

**(301) 280-1992**

(Registrant’s TelephoneNumber, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed allreports required to be filed by Section 13 or 15(d) of the ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.                                                               Yes      x      No o

 

Indicate by check mark whether the registrant is a large acceleratedfiler, an accelerated filer, a non-accelerated filer, or a smaller reportingcompany. See definitions of “large accelerated filer,” “accelerated filer,” and“smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

| Large  accelerated filer o                     |   | Accelerated  filer o         |
|------------------------------------------------|--------|-----------------------------------|
|                                           |   |                              |
| Non-accelerated  filer o                       |   | Smaller  reporting company x |
| (Do not check if  a smaller reporting company) |   |                              |

 

Indicate by check mark whether the registrant is ashell company (as defined in Rule 12b-2 of the Exchange Act).
|   |   | Yes | o | No   x |
|--------|--------|-----|---|------------------|

 

51,553,527****sharesof RegeneRx Biopharmaceuticals, Inc. Common Stock, par value $0.001 pershare, were outstanding as of May 6, 2008.

 

 

 

----

 

**EXPLANATORY NOTE**

 

This Amendment No. 1 to our Quarterly Report on Form 10-Q forthe period ended March 31, 2008 (the “Report”), filed on May 15,2008, is being filed solely to amend exhibits 31.1 and 31.2, which inadvertently omitted certain required language. Theseamendments speak as of the original filing date of the Report. No other changeshave been made to the Report.

 

2

----

 

**Item 6.            Exhibits**

 

| **Exhibit No.** | ** ** | **Description of Exhibit**                                           | ** ** | **Reference**  |
|----------------------|------------|--------------------------------------------------------------------------------|------------|----------------|
|                 |       |                                                                           |       |           |
| 31.1 & 31.2 |       | Certifications Pursuant to Section 302 of the  Sarbanes-Oxley Act of 2002 |       | Filed herewith |

 

3

----

 

**SIGNATURES**

 

In accordance withthe requirements of the Exchange Act, the registrant caused this report to besigned on its behalf by the undersigned, thereunto duly authorized.

 

 
|   |               |   |   | RegeneRx  Biopharmaceuticals, Inc. |
|--------|--------------------|--------|--------|-----------------------------------------|
|   |               |   |   |                                    | (Registrant) |
|   |               |   |   |                                    |
|   |               |   |   |                                    |
| Date:  | July 31, 2008 |   | By:    | /s/J.J. Finkelstein                     |
|   |               |   |   | J.J. Finkelstein                        |
|   |               |   |   | President and Chief Executive Officer   |
|   |               |   |   | (duly authorized officer)               |
|   |               |   |   |                                    |
|   |               |   |   |                                    |
|   |               |   | By:    | /s/C. Neil Lyons                        |
|   |               |   |   | C. Neil Lyons                           |
|   |               |   |   | Chief Financial Officer                 |
|   |               |   |   | (principal financial officer)           |

 

4

----